Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study
Zhen-Hua Chen,Xiu-Ping Zhang,Yu-Gang Lu,Le-Qun Li,Min-Shan Chen,Tian-Fu Wen,Wei-Dong Jia,Dong Zhou,Jing Li,Ding-Hua Yang,Zuo-Jun Zhen,Yi-Jun Xia,Rui-Fang Fan,Yang-Qing Huang,Yu Zhang,Xiao-Jing Wu,Yi-Ren Hu,Yu-Fu Tang,Jian-Hua Lin,Fan Zhang,Cheng-Qian Zhong,Wei-Xing Guo,Jie Shi,Joseph Lau,Shu-Qun Cheng
DOI: https://doi.org/10.1007/s12072-020-10032-2
Abstract:Background: Liver resection for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) offers a chance of cure, although survival is often limited. The actual 3-year survival and its associated prognostic factors have not been reported. Methods: A nationwide database of HCC patients with PVTT who underwent liver resection with 'curative' intent was analyzed. The clinicopathologic characteristics, the perioperative, and survival outcomes for the actual long-term survivors were compared with the non-long-term survivors (patients who died within 3 years of surgery). Univariable and multivariable regression analyses were performed to identify predictive factors associated with long-term survival outcomes. Results: The study included 1590 patients with an actuarial 3-year survival of 16.6%, while the actual 3-year survival rate was 11.7%. There were 171 patients who survived for at least 3 years after surgery and 1290 who died within 3 years of surgery. Multivariable regression analysis revealed that total bilirubin > 17.1 μmol/l, AFP > 400 ng/ml, types of hepatectomy, extent of PVTT, intraoperative blood loss > 400 ml, tumor diameter > 5 cm, tumor encapsulation, R0 resection, liver cirrhosis, adjuvant TACE, postoperative early recurrence (< 1 year), and recurrence treatments were independent prognostic factors associated with actual long-term survival. Conclusion: One in nine HCC patients with PVTT reached the long-term survival milestone of 3 years after resection. Major hepatectomy, controlling intraoperative blood loss, R0 resection, adjuvant TACE, and 'curative' treatment for initial recurrence should be considered for patients to achieve better long-term survival outcomes.